A nonlinear mixed effects IVIVC model for multi-release drug delivery systems

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 35, Issue 4, 2008, Pages 423-441

  Rossenu, S ^a   Gaynor, C ^b   Vermeulen, A ^a   Cleton, A ^c   Dunne, A ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Controlled release; Dissolution; In vitro in vivo correlation; Population pharmacokinetics

Indexed keywords

ETHYL CELLULOSE; GALANTAMINE; HYDROXYPROPYLMETHYLCELLULOSE; PHTHALIC ACID DIETHYL ESTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DUAL RELEASE FORMULATION; EXTERNAL VALIDITY; FEMALE; HUMAN; IN VITRO IN VIVO CORRELATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONLINEAR SYSTEM; PERFORMANCE; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

ADOLESCENT; ADULT; ALGORITHMS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; GALANTAMINE; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; NOOTROPIC AGENTS; POPULATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOLUBILITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 52549102470     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-008-9095-3     Document Type: Article

References (19)

1. FDA's Guidance for Industry: extended release oral dosage forms: development, evaluation, and application of in vitro/in vivo correlations, 1997
2. A Dunne C Gaynor J Davis 2005 Deconvolution based approach for level A in vivo-in vitro correlation modeling: statistical considerations Clin Res Regul Aff 22 1 14 10.1081/CRP-200054957
3. Wing GM (1991) A primer on integral equations of the first kind-the problem of deconvolution and unfolding. Society for Industrial and Applied Mathematics, Philadelphia
4. T O'Hara S Hayes J Davis J Devane T Smart A Dunne 2001 In vivo-in vitro (IVIVC) modeling incorporating a convolution step J Pharmacokinet Pharmacodyn 28 277 298 10.1023/A:1011531226478
5. Gillespie WR (1997) Convolution-based approaches for in vitro-in vivo correlation modeling. In: Advances in experimental medicine and biology; In vitro-in vivo Correlations. Plenum Press, New York, 423:53-65
6. A Schrattenholz EFR Pereira U Roth KH Weber EX Albuquerque A Maelicke 1996 Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands Mol Pharmacol 49 1 6
7. VD Tonkopii VB Prozorovskii IM Suslova 1976 Interaction of reversible inhibition with catalytic centres and allosteric site of cholinesterases Bull Exp Biol Med 82 1180 1183 10.1007/BF00785549
8. T Thomsen H Kewitz 1990 Selective inhibition of human acetylcholinesterase by Galantamine in vitro and in vivo Life Sci 46 1553 1558 10.1016/0024-3205(90)90429-U
9. PN Tariot PR Solomon JC Morris 2000 A 5-month, randomized, placebo-controlled trial of Galantamine in AD Neurology 54 2269 2276
10. MA Raskind ER Peskind T. Wessel 2000 Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension Neurology 54 2261 2268
11. GK Wilcock S Lilienfeld E Gaens 2000 Efficacy and safety of Galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial BMJ 321 1 7 10.1136/bmj.321.7274.1445
12. Paskov DS (1986) Galanthamine. The handbook of experimental pharmacology. Spring Verlag, Berlin, 79:653-672
13. H Kewitz 1997 Pharmacokinetics and metabolism of Galantamine Drugs Today (Barc) 33 265 272
14. Johnson NL, Kotz S, Balakrishnan N (1994) Continuous univariate distributions. Vol. 1, Wiley New York
15. P Costa JMS Lobo 2001 Modeling and comparison of dissolution profiles Eur J Pharm Sci 13 123 133 10.1016/S0928-0987(01)00095-1
16. JA Goldsmith N Randall SD Ross 1978 On methods of expressing dissolution rate data J Pharm Pharmacol 30 347 349
17. F Langenbucher 1972 Linearization of dissolution rate curves by the Weibull distribution J Pharm Pharmacol 24 979 981
18. Gibaldi M, Perrier D (1982) Pharmacokinetics. 2nd edn. Dekker Inc., New York
19. Beal, SL, Sheiner, LB (eds) (1989-1998) NONMEM users guides I-VIII. Globomax, Hanover